Found 22 articles
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage via microbiome-driven liquid biopsy technology, announced a collaboration with the University of New South Wales, Sydney for a $4 million grant from the Australian Government to fund research into hepatocellular carcinoma, the most common type of primary liver cancer.
New Clinical Study Investigates Using Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients
Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing is underway.
Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer
Sirnaomics, Inc. announced today dose administration for the first patient in a Phase 1 U.S. clinical study for liver cancer treatment.
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
Gilead Sciences, Inc. announced that more than 70 abstracts from the company’s liver disease programs will be presented at The International Liver Congress™ 2021 taking place from June 23-26.
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced new data from the Phase II advanced liver cancer study
Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer
Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that one of the acquisition companies of the previously-announced Biocogency merger, Bebig LLC ( http://en.bebig.ru ), received an updated Russian registration certificate for the production and sale of nanostructured microspheres based on yttrium-90, used in the treatment of both primary and metastatic liver lesions. This will start industrial production and sale of ready-made
Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT), and is due to receive a U.S. $10 million payment. The development and l
Q Biomed to Scale up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing
Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines NEW YORK , July 22, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to contin
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data collection date is six months after the last patient in. “Tumor Treating Fields therapy has demonstrated efficacy in in vitr
Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I
Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers . Enzo’s patent is directed to methods for treating hepatocellular carcinoma (HCC), the
Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer
Encouraging preliminary results about the iBiopsy® clinical development plan on liver cancer and the technological methods therein Development of a fibrosis biomarker from CT scan imaging A better performing biomarker compared to existing imaging biomarkers
Tecentriq is an anti-PD-L1 checkpoint inhibitor. Avastin binds to the VEGF protein, which plays a significant role in the development and maintenance of blood vessels by cancer cells.
Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Can-Fite BioPharma Ltd .recently completed Phase II trial and planned Phase III trial in this indication.
AstraZeneca’s Imfinzi (durvalumab) and tremelimumab were granted Orphan Drug designation by the U.S. Food and Drug Administration as a possible treatment for hepatocellular carcinoma.
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
6/24/2019The drug failed to meet statistical significance for overall survival. However, the company is putting a positive spin on it, saying it showed a clear improvement trend in OS for patients treated with Opdivo compared to sorafenib.
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, recently developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.